Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-10-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
北京市康达律师事务所关于新乡拓新药业股份有限公司2022年限制性股票激励计划首次授予相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2022 restricted stock incentive plan initial grant. It discusses the approval, authorization, and compliance of the stock incentive plan, referencing relevant laws and regulations. It is not a financial report, earnings release, or management discussion. It is a legal opinion related to a capital incentive plan, which is a specialized legal document rather than a financial or regulatory filing. It does not announce voting results, changes in management, or merger activity. The document is not a report publication announcement or a certification. Given the nature of the document as a legal opinion on a stock incentive plan, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2022-10-20 Chinese
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "新乡拓新药业股份有限公司2022年第三季度报告" which translates to "Xinxiang Tuoxin Pharmaceutical Co., Ltd. 2022 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the third quarter of 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period ending September 30, 2022. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 13,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-20 Chinese
关于向2022年限制性股票激励计划激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted stock under a 2022 restricted stock incentive plan by the company 新乡拓新药业股份有限公司. It includes specifics such as the grant date, number of shares, price, allocation among executives and key personnel, performance conditions, approval procedures, legal and financial advisor opinions, and compliance with regulatory requirements. The content focuses on the issuance of shares to management and key employees as part of a stock incentive plan, which is a capital/financing activity related to the company's equity structure. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. The document is comprehensive and substantive, not a brief notice or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-10-20 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司2022年限制性股票激励计划首次授予事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the "2022 Restricted Stock Incentive Plan First Grant" for a company. It contains detailed analysis and opinions on the approval procedures, grant conditions, and impact on financial status related to a restricted stock incentive plan. The document is a standalone advisory report prepared by an independent financial advisor, focusing on a specific capital incentive event rather than a full annual or quarterly financial report. It does not contain comprehensive financial statements or earnings data but rather an advisory opinion on a capital incentive plan. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock incentive plans. The document length is 7667 characters, which is substantive and not a mere announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2022-10-20 Chinese
第四届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 4th Board of Directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and voting results on specific agenda items such as approval of the 2022 Q3 report and a restricted stock incentive plan. The content focuses on board decisions and governance matters rather than presenting full financial statements or detailed financial analysis. The document length is short (1196 characters) and it serves as an official disclosure of board meeting resolutions. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2022-10-20 Chinese
监事会关于2022年限制性股票激励计划首次授予激励对象名单（首次授予日）的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the initial grant list of a 2022 restricted stock incentive plan for a company. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and approval of the stock grant. There is no financial data, earnings information, or detailed report content. The document is an announcement related to a stock incentive plan, specifically confirming the grant and eligibility of recipients. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance announcement and verification, not a full report or financial statement.
2022-10-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.